Signal Genetics (NASDAQ: MGEN) and BioTelemetry (NASDAQ:BEAT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Valuation & Earnings

This table compares Signal Genetics and BioTelemetry’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Signal Genetics $2.63 million 67.15 -$23.96 million N/A N/A
BioTelemetry $211.19 million 5.44 $41.34 million $1.50 23.67

BioTelemetry has higher revenue and earnings than Signal Genetics.

Risk & Volatility

Signal Genetics has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. Comparatively, BioTelemetry has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.

Profitability

This table compares Signal Genetics and BioTelemetry’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Signal Genetics -796.06% -84.64% -66.29%
BioTelemetry 21.03% 18.75% 12.70%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Signal Genetics and BioTelemetry, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Signal Genetics 0 0 3 0 3.00
BioTelemetry 0 0 5 0 3.00

Signal Genetics currently has a consensus target price of $23.00, suggesting a potential upside of 179.81%. BioTelemetry has a consensus target price of $45.75, suggesting a potential upside of 28.87%. Given Signal Genetics’ higher possible upside, equities research analysts clearly believe Signal Genetics is more favorable than BioTelemetry.

Insider and Institutional Ownership

16.5% of Signal Genetics shares are owned by institutional investors. Comparatively, 76.7% of BioTelemetry shares are owned by institutional investors. 44.4% of Signal Genetics shares are owned by company insiders. Comparatively, 9.6% of BioTelemetry shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

BioTelemetry beats Signal Genetics on 7 of the 11 factors compared between the two stocks.

Signal Genetics Company Profile

Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company’s MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.

BioTelemetry Company Profile

BioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Company’s research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. (Cardiocore).

Receive News & Stock Ratings for Signal Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Signal Genetics Inc. and related stocks with our FREE daily email newsletter.